FDA Expands Eli Lilly's ALIMTA (pemetrexed) Label To Include Combination With KEYTRUDA (pembrolizumab) And Carboplatin As First-Line Treatment For Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective Of PD-L1 Expression